Where are LVADs headed in the future?

Abbott (NYSE:ABT) became the dominant provider of left ventricular assist devices (LVADs) after Medtronic’s decision to leave the market last year.

The Abbott HeartMate 3‘s advantages include its Full MagLev flow technology — which involves a free-floating magnetically levitated rotor that prevents surface-to-surface contact that could cause blood trauma. In addition, system batteries provide up to 17 hours of uninterrupted power, and the LVAD’s creators designed the system’s HeartMate Touch communications system to be intuitive and user-friendly.

Join us at DeviceTalks Boston on May 10-11, 2022, and find out where top Abbott officials would like to take LVADs next to better sustain heart failure patients’ lives.

Abbott officials on the panel include Chris Cotter, principal R&D engineer, Chad Dague, staff systems engineer, and Kevin Bourque, VP of R&D.

(Go to DeviceTalks Boston’s site to register!)